Circulating galectin-3 correlates with angiogenetic factors, indicators of nutritional condition and systemic inflammation in patients with thyroid cancer
暂无分享,去创建一个
T. Shimura | T. Fukushima | S. Takenoshita | T. Nakajima | Shinichi Suzuki | K. Nakano | Satoshi Suzuki | Masaru Noda | M. Shibata | I. Nakamura | K. Gonda | Shun Chida | Shinichi Suzuki
[1] A. Shivarudrappa,et al. Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. , 2015, Journal of clinical and diagnostic research : JCDR.
[2] E. Lee,et al. Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings , 2015, Journal of Endocrinological Investigation.
[3] E. Yılmaz,et al. Serum Galectin-3: diagnostic value for papillary thyroid carcinoma. , 2015, Ulusal cerrahi dergisi.
[4] Yunhui Li,et al. Serum Galectin-3 as a Potential Marker for Gastric Cancer , 2015, Medical science monitor : international medical journal of experimental and clinical research.
[5] R. Sun,et al. Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack , 2014, The Journal of Biological Chemistry.
[6] A. Raz,et al. Galectin-3 in angiogenesis and metastasis. , 2014, Glycobiology.
[7] M. Schlumberger,et al. Progress in molecular-based management of differentiated thyroid cancer , 2013, The Lancet.
[8] C. Chen,et al. Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium , 2013, Clinical Cancer Research.
[9] M. Bullock,et al. Serum biomarkers of papillary thyroid cancer , 2013, Journal of Otolaryngology - Head & Neck Surgery.
[10] R. Ni,et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.
[11] L. Santarpia,et al. RET TKI: Potential Role in Thyroid Cancers , 2012, Current Oncology Reports.
[12] Suk-Kyeong Kim,et al. The BRAFV600E mutation is associated with malignant ultrasonographic features in thyroid nodules , 2011, Clinical endocrinology.
[13] S. Tsuboi,et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O‐glycans , 2011, EMBO Journal.
[14] M. Nikiforova,et al. Both BRAF V600E Mutation and Older Age (≥65 Years) are Associated with Recurrent Papillary Thyroid Cancer , 2011, Annals of Surgical Oncology.
[15] Thijs J. Hagenbeek,et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes , 2010, Proceedings of the National Academy of Sciences.
[16] I. Paunovíc,et al. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors , 2010, Journal of Cancer Research and Clinical Oncology.
[17] A. Miyauchi,et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. , 2008, Biochemical and biophysical research communications.
[18] F. Pattou,et al. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. , 2008, Thyroid : official journal of the American Thyroid Association.
[19] H. Kanayama,et al. Serum level of galectin-3 in human bladder cancer. , 2008, The journal of medical investigation : JMI.
[20] D. Hsu,et al. Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. , 2006, The American journal of pathology.
[21] G. Ghanem,et al. High serum galectin‐3 in advanced melanoma: preliminary results , 2006, Clinical and experimental dermatology.
[22] A. Raz,et al. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells , 2002, Oncogene.
[23] Isabelle Camby,et al. Galectins and cancer. , 2002, Biochimica et biophysica acta.
[24] Michael J. Davis,et al. Shuttling of galectin-3 between the nucleus and cytoplasm. , 2002, Glycobiology.
[25] Lana Barkin. “Dis-ease”: , 2000, Ritual, Myth, and Mysticism in the Work of Mary Butts.
[26] N. Tinari,et al. Concentrations of galectin-3 in the sera of normal controls and cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] H. Inohara,et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. , 1997, Cancer Research.
[28] H. Matsuda,et al. Rapid turnover proteins as a prognostic indicator in cancer patients , 1995, Surgery Today.
[29] L. Delbridge,et al. Increasing incidence and changing presentation of thyroid cancer over a 30‐year period , 1995, The British journal of surgery.
[30] J. Becker,et al. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. , 1993, Journal of immunology.
[31] D. Johnston,et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.
[32] J. Becker,et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.
[33] E. Kaplan,et al. Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.
[34] A. Spiekerman,et al. Prealbumin: a parameter of visceral protein levels during albumin infusion. , 1982, JPEN. Journal of parenteral and enteral nutrition.
[35] F. Delpeuch,et al. The effect of iron-deficiency anaemia on two indices of nutritional status, prealbumin and transferrin , 1980, British Journal of Nutrition.
[36] G. Bozkaya,et al. Prognostic Significance of Serum Galectin-3 Levels in Patients with Hepatocellular Cancer and Chronic Viral Hepatitis , 2015, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[37] M. Notarnicola,et al. Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. , 2010, Immunopharmacology and immunotoxicology.
[38] R. Kiss,et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. , 2008, Oral oncology.
[39] D. Kerr,et al. The epidemiology of thyroid carcinoma. , 1993, Critical reviews in oncogenesis.
[40] N. Trapeznikov,et al. [General mechanisms of metastasis of malignant neoplasms into bones]. , 1977, Khirurgiia.